479 related articles for article (PubMed ID: 11156401)
41. Cell cycle-dependent inhibition of p34cdc2 synthesis by transforming growth factor beta 1 in cycling epithelial cells.
Eblen ST; Fautsch MP; Burnette RJ; Joshi P; Leof EB
Cell Growth Differ; 1994 Feb; 5(2):109-16. PubMed ID: 8180123
[TBL] [Abstract][Full Text] [Related]
42. Transforming growth factor-beta 1 inhibits cyclin D1 expression in intestinal epithelial cells.
Ko TC; Sheng HM; Reisman D; Thompson EA; Beauchamp RD
Oncogene; 1995 Jan; 10(1):177-84. PubMed ID: 7824270
[TBL] [Abstract][Full Text] [Related]
43. The bioactivity of transforming growth factor-beta1 can be regulated via binding to dermal collagens in mink lung epithelial cells.
Shibuya H; Okamoto O; Fujiwara S
J Dermatol Sci; 2006 Mar; 41(3):187-95. PubMed ID: 16337361
[TBL] [Abstract][Full Text] [Related]
44. Insulin-like growth factor binding protein-2 mediates the inhibition of DNA synthesis by transforming growth factor-beta in mink lung epithelial cells.
Dong F; Wu HB; Hong J; Rechler MM
J Cell Physiol; 2002 Jan; 190(1):63-73. PubMed ID: 11807812
[TBL] [Abstract][Full Text] [Related]
45. Adenovirus-mediated human topoisomerase IIalpha gene transfer increases the sensitivity of etoposide-resistant human and mouse breast cancer cells.
Asano T; Kleinerman ES; Zwelling LA; Zhou Z; Fukunaga Y
Acta Oncol; 2005; 44(3):240-7. PubMed ID: 16076696
[TBL] [Abstract][Full Text] [Related]
46. Transforming growth factor-beta1 activates interleukin-6 expression in prostate cancer cells through the synergistic collaboration of the Smad2, p38-NF-kappaB, JNK, and Ras signaling pathways.
Park JI; Lee MG; Cho K; Park BJ; Chae KS; Byun DS; Ryu BK; Park YK; Chi SG
Oncogene; 2003 Jul; 22(28):4314-32. PubMed ID: 12853969
[TBL] [Abstract][Full Text] [Related]
47. Differential cell cycle-specificity for chromosomal damage induced by merbarone and etoposide in V79 cells.
Wang L; Roy SK; Eastmond DA
Mutat Res; 2007 Mar; 616(1-2):70-82. PubMed ID: 17174356
[TBL] [Abstract][Full Text] [Related]
48. TGF-beta1-induced cell growth arrest and partial differentiation is related to the suppression of Id1 in human hepatoma cells.
Damdinsuren B; Nagano H; Kondo M; Natsag J; Hanada H; Nakamura M; Wada H; Kato H; Marubashi S; Miyamoto A; Takeda Y; Umeshita K; Dono K; Monden M
Oncol Rep; 2006 Feb; 15(2):401-8. PubMed ID: 16391861
[TBL] [Abstract][Full Text] [Related]
49. Transforming growth factor beta1 selectively regulates ferritin gene expression in malignant H-ras-transformed fibrosarcoma cell lines.
Lo J; Hurta RA
Biochem Cell Biol; 2000; 78(4):527-35. PubMed ID: 11012093
[TBL] [Abstract][Full Text] [Related]
50. Potential role of transforming growth factor beta1 in drug resistance of tumor cells.
Stoika R; Yakymovych M; Souchelnytskyi S; Yakymovych I
Acta Biochim Pol; 2003; 50(2):497-508. PubMed ID: 12833174
[TBL] [Abstract][Full Text] [Related]
51. Ectopic expression of Cdk6 circumvents transforming growth factor-beta mediated growth inhibition.
Zhang F; Taipale M; Heiskanen A; Laiho M
Oncogene; 2001 Sep; 20(41):5888-96. PubMed ID: 11593394
[TBL] [Abstract][Full Text] [Related]
52. Differential induction of early response genes by adrenomedullin and transforming growth factor-beta1 in human lung cancer cells.
Kane S; Prentice MA; Mariano JM; Cuttitta F; Jakowlew SB
Anticancer Res; 2002; 22(3):1433-44. PubMed ID: 12168820
[TBL] [Abstract][Full Text] [Related]
53. Overexpression of USF increases TGF-beta1 protein levels, but G1 phase arrest was not induced in FRTL-5 cells.
Kim KS; Jung HS; Chung YJ; Jung TS; Jang HW; Lee MS; Kim KW; Chung JH
J Korean Med Sci; 2008 Oct; 23(5):870-6. PubMed ID: 18955796
[TBL] [Abstract][Full Text] [Related]
54. Expression and relationship between topoisomerase I and II alpha genes in tumor and normal tissues in esophageal, gastric and colon cancers.
Kim R; Ohi Y; Inoue H; Toge T
Anticancer Res; 1999; 19(6B):5393-8. PubMed ID: 10697567
[TBL] [Abstract][Full Text] [Related]
55. Transforming growth factor beta 1 inhibits mouse keratinocytes late in G1 independent of effects on gene transcription.
Alexandrow MG; Moses HL
Cancer Res; 1995 Sep; 55(17):3928-32. PubMed ID: 7641212
[TBL] [Abstract][Full Text] [Related]
56. Cyclic AMP-dependent protein kinase type I is involved in hypersensitivity of human breast cells to topoisomerase II inhibitors.
Tortora G; Ciardiello F; Damiano V; Pepe S; Bianco C; di Isernia G; Davies SL; North P; Harris AL; Hickson ID
Clin Cancer Res; 1995 Jan; 1(1):49-56. PubMed ID: 9815886
[TBL] [Abstract][Full Text] [Related]
57. Type V collagen is an epithelial cell cycle inhibitor that is induced by and mimics the effects of transforming growth factor beta1.
Parekh TV; Wang XW; Makri-Werzen DM; Greenspan DS; Newman MJ
Cell Growth Differ; 1998 May; 9(5):423-33. PubMed ID: 9607563
[TBL] [Abstract][Full Text] [Related]
58. Novel Cdk inhibitors restore TGF-beta sensitivity in cdk4 overexpressing epithelial cells.
Soni R; Fretz H; Muller L; Schoepfer J; Chaudhuri B
Biochem Biophys Res Commun; 2000 Jun; 272(3):794-800. PubMed ID: 10860833
[TBL] [Abstract][Full Text] [Related]
59. Daurinol, a catalytic inhibitor of topoisomerase IIα, suppresses SNU-840 ovarian cancer cell proliferation through cell cycle arrest in S phase.
Kang K; Nho CW; Kim ND; Song DG; Park YG; Kim M; Pan CH; Shin D; Oh SH; Oh HS
Int J Oncol; 2014 Aug; 45(2):558-66. PubMed ID: 24841075
[TBL] [Abstract][Full Text] [Related]
60. Down-regulation of topoisomerase IIalpha in CEM cells selected for merbarone resistance is associated with reduced expression of Sp3.
Mo YY; Wang Q; Beck WT
Cancer Res; 1997 Nov; 57(22):5004-8. PubMed ID: 9371492
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
